ANN ARBOR, Mich., Dec. 21, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, announces today that Kim Thompson, the Company’s CEO, issued a letter to shareholders. The full text is as follows:

With the holiday season upon us, I’d like to reach out to all of our team members, especially our shareholders, to express my appreciation and great expectations for our production and commercialization in 2022.

Yes, the holidays are just around the corner and we’re heading into 2022 in what is, by far, our strongest financial and fundamental position, so we’re excited about the coming advancements for Kraig Labs and anticipate spider silk’s commercial success in the New Year.

As you know, 2021 presented many new challenges, mostly centered on navigating the COVID-19 regulations, but addressing these with smart solutions has enriched Kraig and Prodigy Textiles, our Vietnamese subsidiary.

For example, after confirming proof of our production concept, we introduced the first automation into Prodigy’s workflow five months ago. This equipment has drastically improved our material handling and has allowed us to grow the size of our silkworm colony without bringing in additional labor. More importantly, this equipment is playing a key role in our quality control system and is the backbone on which we are building out our production capacity. This upgrade to our operations has delivered a sustained quality to our silkworm colony that was previously not attainable.

However, the next phase of this initiative is a game-changer; Prodigy’s fully equipped laboratory is a new onsite capacity that was designed to mirror the capabilities of Kraig’s US R&D headquarters and provide in-process quality and genetic screening. Partnered with the automated production equipment, the new lab will provide Prodigy with the same world-class genetic screening capabilities that were critical in Kraig’s creation of spider silk transgenics. Once these capabilities are online, we anticipate judiciously scaling output to metric tons.

I believe that the importance of that milestone cannot be overstated, because it positions us to move on to the next chapter of our business model. Fulfilling the years’ long material request backlog, which is key to securing additional commercialization agreements. Plus, we plan on working with some inventors and product developers whose imagination may take spider silk to yet unknown frontiers.

Dr. Miller, who completed his Ph.D. and postdoctoral work at Yale, joined Kraig’s R&D team in July. He’s already made significant contributions in advancing the commercialization of the Company’s new lines of nearly pure spider silk and the silkworm immunity enhancement program. Dr. Miller has recharged our R&D team with new energy and expertise. His contributions and ideas have opened the potential for several additional revenue streams reaching far beyond textiles. We’re excited to see what he unveils over the next year.

Of course, most of these breakthroughs were made possible by the $5 million funding that the Company secured through its partnering with a substantial investment bank based in New York. This marks the largest capital investment in the Company’s history. Drawing this type of attention and confidence from sophisticated investors is exciting and reaffirming of our belief in the markets for spider silk and the future of Kraig Labs. As our production operations continue to grow, we are positioned to see additional potential institutional funding in 2022.

Kraig Labs and Prodigy Textiles kindly thank you for your trust and continuing support, because we accomplished so much, together. We hope that you are surrounded by loved ones this holiday season and that, like Kraig, your best days remain ahead.

With warmest holiday greetings and best wishes for the New Year,

Kim Thompson and the entire Kraig Labs’ family

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Dec. 10, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, announces today that its spider silk was featured in a new episode of the BBC Earth’s “Inspired By Nature” series.  

To view a portion of the episode, please go to BBC Earth’s Facebook page and look for the “Bulletproof material made from a spider’s web” post at: https://www.facebook.com/bbcearth/videos/427557478860613/

“We don’t need to reinvent the wheel, we don’t need to try to do something better than nature has, we simply need to find ways to reproduce what nature has already done,” said Jon Rice to BBC Earth when asked where Kraig Labs draws its inspiration.

Sample images of the Company’s recombinant spider silk silkworms and materials featured in the episode found on the Company’s website at www.kraiglabs.com/InspiredByNature

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About BBC Earth

Celebrating nature, science, space and the human race, BBC Earth brings you face to face with heart-pounding action, mind-blowing ideas and the sheer wonder of being part of this amazing planet we call home.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Dec. 09, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, announces today that it is expanding the footprint of its Vietnam based operations with the planting of several acres of mulberry trees at its recombinant spider silk production campus.

Agricultural production cycles in Vietnam have historically left the Company with limited access and high costs for the continuous supply of fresh mulberry needed during the winter months. With the expansive lands available in its new operations headquarters, the Company has begun planting mulberry on the more than 7 acres of fertile field land it controls.

The Company will continue to partner with local farming cooperatives to source the majority of its mulberry during the summer months. However, these onsite fields will eliminate the need for seasonal slowdowns that have impacted winter production.   Previously, the Company was forced to purchase mulberry from the broader markets. Direct control over its own mulberry fields will remove concerns of pesticide overspray from adjoining farms that have been difficult to monitor in previous winters.

“Kraig Labs has always prided itself on being scrappy and self-reliant. Our team at Prodigy Textiles is no different. The move to this new larger facility and these mulberry fields allow us the ability to create a truly self-sustaining spider silk production campus,” said COO Jon Rice. “The final piece of this equation will be the lab equipment scheduled for installation later this month. With that, Prodigy Textile will have the means, ability, and facilities to stand on its own as the world’s first truly sustainable supplier of spider silk super fibers.”

Sample images of the new production campus and the mulberry fields can be found on the Company’s website at www.kraiglabs.com/MulberryFields.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, announces today that it has begun production of the fourth generation of its specialized spider silk silkworms at its new production campus.

Having successfully completed the third generation of silkworms in mid-November, the Company continues to grow the size and strength of its silkworm colony as it presses forward with continuous production operations. Since transitioning all of its operations to this campus, in August of this year, the Company has increased the size of each successive production run and has seen a significant improvement in production yields.

Kraig Labs relocated Prodigy, the Company’s Vietnamese subsidiary, to this new facility in the heart of one of Quang Nam’s agricultural districts to leverage better access to fresh mulberry and the temperate climate. Covering nearly 10 acres, this campus includes multiple buildings, including a dedicated laboratory, a separate rearing house built explicitly for silk production, and more than 7 acres of fertile land for onsite mulberry production.

As the Company continues to grow its operational capacity, its existing supply of raw silk yarn is slated for spinning into custom yarns and composite fabrics that it will sell under its joint venture SpydaSilk brand. The Company is currently assessing a number of potential textile mill partners to produce these fabrics as it works within the capacity limitations and lingering worker shortages imposed by COVID-19 restrictions.

“With the beginning of fourth-generation production at the new campus, we are exactly where we need to be,” said COO Jon Rice. “The measured and staged growth plan that we have put in place for this new facility has proven to be incredibly effective, resulting in consistent and reliable capacity expansion. Later this month, we will begin the next evolution of our operation with the opening of the onsite laboratory. This new lab will allow for in-process genetic screening and the tools to immediately increase our output by at least ten times and our vision of metric ton scale spider silk production.”

Sample images of the new production campus and third-generation silkworms in production can be found on the Company’s website, at www.kraiglabs.com/prodigyHQ.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Oct. 28, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, shares today that easing travel restrictions and re-opening business operations throughout Vietnam has re-energized the Company as it moves forward with the production of finished goods utilizing its specialized recombinant spider silk.

Safety protocols and restrictions enacted at the onset of the COVID-19 pandemic in Vietnam led to closures and slowdowns of many businesses throughout the country, most notably in Ha Noi and Ho Chi Minh City. The majority of these restrictions did not directly impact the Company’s subsidiary, so Prodigy Textiles, located in central Vietnam, did not stop the production of its specialized silkworms. However, those shutdowns affected Prodigy’s employees and the Company, including delayed laboratory equipment deliveries, which delayed operational growth, and slowdowns at yarn spinners and weavers, which limited the Company’s ability to convert its raw silk into finished fabrics and garments.  

Now, as these restrictions are lifting, Kraig Labs is ready to accelerate the scale-up of silkworm production with the scheduled delivery and installation of new quality control (“QC”) lab equipment.   In the absence of the genetic screening that this new QC lab equipment will enable, the Company intentionally maintained production below peak capacity to ensure a stable and healthy silkworm colony. Once installed, Prodigy’s facility will have onsite control systems far more advanced than nearly all silk producers.

This month brought several significant regulatory orders easing those restrictions, once again allowing the movement and travel for crucial goods, services, and personnel throughout the country. With the re-opening of textile mills and yarn spinners, Kraig Labs is now resuming work to produce the custom yarns and spider silk fabrics for the launch of SpydaSilk^TM apparel, a joint development partnership with Kings Golden Harvest, PTE LTD.

“We are pleased to see conditions in Vietnam improving for its people and its economy,” said Kraig Labs COO Jon Rice. “In the coming weeks, we expect to receive and install several pieces of lab equipment delayed due to lockdowns. This quality assurance equipment will play a key role in our continued production expansion. Most critically, with this re-opening, we can once again work with the textile mills to weave our silk into the finished fabrics for the first garments for SpydaSilk and to supply materials to the numerous other brands eager to incorporate spider silk into their products.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

Immunity enhanced silkworms provide licensing opportunities into the broader $14B¹ silk industry

ANN ARBOR, Mich., Oct. 19, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has begun challenge testing on of its immunity enhanced silkworms. These silkworms were developed by Kraig Labs to combat viral and fungal infections that result in significant losses in global silk production.

As much as 50% of losses in global silk production are the result of a single virus. Up to 75% of all silk producers have reported losses from this virus, according to a 2020 research paper. These losses account for millions and potentially billions of dollars of lost economic production each year. Often found in soil and plants – quickly spread and with no effective treatment – this virus can be devastating to small and large producers alike. With this announcement, Kraig Labs is creating a solution for the global $14B silk market.

By adapting its genetic engineering technologies, used to produce recombinant spider silk, Kraig Labs has developed multiple lines of silkworms that incorporate a genetic defense against this virus and other prominent silkworm diseases. As designed, the silkworm’s immune system will target and eliminate any copy of the virus DNA, preventing the spread of infection and loss.

Having built a sizeable colony of these immunity-enhanced silkworms, the Company is now undergoing challenge testing at a controlled offsite test location. This remote offsite location was selected to prevent the potential introduction and spread of the virus into Kraig Labs R&D headquarters.

These new disease-resistant silkworms are intended for licensing into the global market for mundane silks to combat key pathogenic viruses and fungi. The Company expects to make these lines of resilient silkworms available for commercial licensing upon the conclusion of successful challenge testing and intends to incorporate this technology into all of its lines of spider silk transgenics.

“With testing now underway, we are excited to see the potential that these new silkworm strains can bring to the broader sericulture industry,” said the Company’s COO, Jon Rice. “Combating these silkworm diseases is an industry-wide challenge. Bringing licensable, immunity-enhanced silkworms to the global silk market advances our business model and aligns with our core focus in commercializing cost-effective and environmentally responsible recombinant spider silk.”  

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Oct. 12, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that its research team has surpassed a crucial milestone in the creation and production of new recombinant spider silks and other key target proteins. The Company is now raising several batches of first-generation transgenics utilizing this new and more efficient process.

These transgenics represent the first implementation of this new knock-out/knock-in multiplex system for silkworms developed by Kraig Labs’ research team. The new approach results in a greater than 60% reduction in process complexity when creating new transgenics and should result in significantly higher yields. Pairing multiplex targeting with co-expression of trans-proteins, this new system should allow the Company to achieve homozygous, germline stable, new transgenics in a fraction of the time.  

Kraig Labs’ research team will monitor these first-generation transgenics over the next 30 days to verify improvements over existing systems. The Company’s research team has already prepared and filed a potential provisional patent to protect this new novel technology.

“Today’s announcement is just the latest in a string of incredible breakthroughs from our research lab. Our team continues to defy conventional wisdom, finding almost unimaginable solutions and unlocking the potential for cost-effective, commercial-scale spider silk production,” said COO Jon Rice. “This breakthrough is the direct result of our exceptionally creative research team. Through an intentional process of seeking out diverse backgrounds and experiences for all positions throughout the organization, we have built a truly extraordinary team.”

While now focused on improving the production of recombinant spider silk, this new gene system is directly applicable to the Company’s accelerating work in non-fibrous and boutique protein production.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

Immunity enhanced silkworms provide licensing opportunities into the broader $14 B¹ silk industry

ANN ARBOR, Mich., Sept. 28, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it is preparing to conduct challenge testing on two lines of immunity enhanced silkworms. These silkworm lines were developed by Kraig Labs to combat two of the biggest challenges facing the global silk production industry.

It has been reported that as much as 50% of all losses in silk production result from a single widespread virus. A 2020 paper cited that 75% of all interviewer silkworm raisers reported losses due to this disease. With no effective treatment, this virus results in countless millions of dollars of economic annually. Kraig Labs realized that technologies it was developing for other applications could be used to significantly reduce these losses in the broader silk industry. The Company has made rapid progress in the development of this new technology.

Specifically designed to target and combat this virus and other pathogens, these new transgenics developed by Kraig Labs, are now preparing to undergo challenge testing. These new disease-resistant lines of silkworms are intended for licensing into the global market for mundane silks to combat pathogenic viruses and fungi. The Company expects to make these lines of resilient silkworms available for commercial licensing shortly after the conclusion of successful challenge testing.

“We are very excited to begin challenge testing for these immunity enhanced silkworm lines,” said COO Jon Rice. “Our intention is to license this technology to silk produces all over the world. This program to produce licensable commercial lines of more robust silkworms is the perfect complement to our core focus, the commercialization of Kraig’s eco-friendly recombinant spider silk.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

___________________

¹ From New Analysis from Global Industry Analysts Reveals Steady Growth for Silk, with the Market to Reach $21 Billion Worldwide by 2026, read more at: https://www.prnewswire.com/news-releases/new-analysis-from-global-industry-analysts-reveals-steady-growth-for-silk-with-the-market-to-reach-21-billion-worldwide-by-2026-301377060.htm

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Sept. 23, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has delivered the first fabric samples to Spydasilk Enterprises (“Spydasilk”). These fabric blends will serve as the basis for developing the Company’s first line of recombinant spider silk apparel.

Spydasilk, a Singapore-based joint venture between Kraig Labs and Kings Group, was formed to produce, market, and sell spider silk-based apparel into the ASEAN region.

These first sample fabrics blend traditional silk with cotton to produce a composite, blended material in line with the design specification requested by the Kings Group’s lead designer. Once these sample fabrics have been tested and approved, the Company plans to begin weaving several thousand yards of finished fabric incorporating its recombinant spider silk.   

The delivery of these fabrics samples marks a significant milestone for the Company, Spydasilk, and the re-opening of Vietnam’s economy. The textile mill that Kraig Labs partnered with to reel and weave its specialized silk, which was closed due to COVID-19, has now re-opened.

“The delivery of the first composite fabrics to Spydasilk is a major advancement for the Company. This first delivery brings us ever closer to the public launch of Spydasilk’s first apparel line and our vision for large-scale commercialization of environmentally responsible and cost-effective spider silk,” said Jon Rice, COO of Kraig Labs.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Sept. 08, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, announces that it is now rearing the second generation of silkworms at the new production headquarters for Prodigy Textiles (“Prodigy”), the Company’s Vietnamese subsidiary.  

Prodigy successfully completed rearing the first batch of the Company’s specialized silkworms at its new production headquarters in August. Kraig Labs recently moved its Vietnam-based production operations to a new facility located in the heart of agriculture in Vietnam. When originally built, this facility was specifically designed for silkworm rearing and silk production. The Company’s factory is now closer to the farms and fields where Prodigy’s mulberry is harvested, providing greater access to raw materials and reducing production costs.

“I could not be more impressed with our team in Vietnam and the unwavering dedication to making Prodigy and Kraig Labs an undeniable success,” said COO Jon Rice. “Having seamlessly completed the move to the new facility and with the kick-off of the second generation of production there, we are well on the way to revolutionizing the global silk markets.”

The current easing of Covid-19 restrictions, in parts of Vietnam, has allowed the Company to move forward with the construction of finished goods. Kraig Labs is now accelerating the production and evaluation of custom-designed fabric blends for its Spydasilk brand.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com